Department of Research, Innlandet Hospital Trust, PB 104, N-2381, Brumunddal, Norway.
Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, N-7491, Trondheim, Norway.
BMC Med Genet. 2020 Jul 9;21(1):146. doi: 10.1186/s12881-020-01082-2.
In population-based studies, the genetic variability of the APOE E alleles have been associated with health outcomes. Health problems are common in subjects with obesity. This study explored associations between the APOE E alleles and comorbidity in subjects with morbid obesity.
The study included consecutive subjects referred for evaluation of bariatric surgery with morbid obesity (defined as BMI > 40 or > 35 kg/m with complications related to obesity). The subjects followed a conservative weight loss program for 6 months before surgery and had a follow-up visit 12 months after surgery. Demographic data and a set psychosomatic scores (musculoskeletal pain, WHO-5 Well-Being Index, Rosenberg Self-Esteem Scale, Hopkins Symptom Check-list 10; Epworth Sleepiness Scale, and Fatigue Severity Scale) were collected, and blood samples were analysed for haematological and biochemical parameters and APOE alleles.
One hundred and forty subjects (men/women: 32 (23%)/108 (77%) with mean age 43.0 (SD 8.7) years and BMI 42.1 (SD 3.8) kg/m were included. One hundred and eight and 92 subjects had data after conservative treatment and 12 months after surgery, respectively. The prevalence of the APOE alleles were: E2E2: 1 (0.7%), E2E3: 13 (9.3%), E2E4: 4 (2.9%), E3E3: 71 (50.7%), E3E4: 47 (33.6%), and E4E4: 4 (2.9%). The prevalence rates were as anticipated in a Norwegian population. The weight loss during conservative treatment and after bariatric surgery was independent of E allele variability. E2 was associated with a significant or clear trend toward improvement of all psychosomatic disorders. There was a significant fall in CRP during the two treatment periods with weight loss. E2 and E4 were significantly associated with high and low CRP, respectively, but no associations were seen between CRP and comorbidity.
The most marked finding was the association between E2 and improvement of all psychosomatic disorders. The positive and negative associations between CRP and E2 and E4, respectively, could indicate effects on inflammation and immunological reactions.
在基于人群的研究中,APOE E 等位基因的遗传变异性与健康结果相关。肥胖人群中常见健康问题。本研究探讨了 APOE E 等位基因与病态肥胖患者合并症之间的关系。
该研究纳入了连续接受肥胖症评估的择期减重手术患者(病态肥胖定义为 BMI>40 或>35kg/m2 伴有肥胖相关并发症)。患者在手术前进行 6 个月的保守减重治疗,并在手术后 12 个月进行随访。收集人口统计学数据和一系列身心评分(肌肉骨骼疼痛、WHO-5 幸福感指数、罗森伯格自尊量表、霍普金斯症状清单 10;爱泼沃斯嗜睡量表和疲劳严重程度量表),并分析血液样本的血液学和生化参数以及 APOE 等位基因。
共纳入 140 名患者(男/女:32(23%)/108(77%),平均年龄 43.0(8.7)岁,BMI 42.1(3.8)kg/m2)。108 名和 92 名患者分别在保守治疗后和手术后 12 个月时具有数据。APOE 等位基因的流行率分别为:E2E2:1(0.7%),E2E3:13(9.3%),E2E4:4(2.9%),E3E3:71(50.7%),E3E4:47(33.6%),E4E4:4(2.9%)。在挪威人群中,预期的流行率为这些水平。保守治疗和减重手术后的体重减轻与 E 等位基因变异性无关。E2 与所有身心障碍的显著或明显改善趋势相关。在两个减重治疗期间,CRP 显著下降。E2 和 E4 与 CRP 高和低分别显著相关,但 CRP 与合并症之间无相关性。
最显著的发现是 E2 与所有身心障碍的改善之间的关联。CRP 与 E2 和 E4 之间的阳性和阴性关联可能表明对炎症和免疫反应的影响。